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Introduction {#sec1}
============

The acquisition of cellular identity during stem cell commitment and differentiation relies on a combination of genetic and epigenetic information that ultimately determines cellular transcriptional outputs. Master transcription factors are responsible for the selection of unique enhancer repertoires and activate a cascade of epigenetic events (e.g., modification of histone tails and loss of DNA methylation) that could lead to cell-specific modulation of gene expression ([@bib15]). Recent advances in genome-wide technologies and bioinformatic data integration allow the elucidation of the molecular mechanisms underlying cell fate decision and lineage development with unprecedented levels of detail by analyzing transcriptional and epigenetic changes occurring at different stages of lineage progression.

Human erythropoiesis is an ideal model for studying mechanisms regulating cell commitment and differentiation as the individual developmental cell stages can be isolated and surface markers as well as the master transcription factors controlling this process are largely known. Erythropoiesis is a multi-step process that includes early erythroid commitment of hematopoietic stem cells (HSC), terminal erythroid differentiation, and reticulocyte maturation ([@bib11]). During early erythroid commitment, HSC give rise to highly proliferating committed erythroid progenitors, erythroid burst-forming units (BFU-Es), and then erythroid colony-forming units (CFU-Es). Erythroid progenitors subsequently undergo terminal differentiation, sequentially producing different populations of erythroid precursors (proerythroblasts, basophilic, polychromatic, and orthochromatic erythroblasts). During this process, cell size is progressively reduced and the cell membrane is reorganized; the cytoplasm first becomes basophilic, as ribosomes accumulate, and then eosinophilic, due to massive production of hemoglobin, whereas the nucleus becomes smaller, as a result of the progressive chromatin condensation. Finally, orthochromatic erythroblasts extrude their nuclei, endoplasmic reticulum, and mitochondria, generating reticulocytes. During maturation, reticulocytes lose the ribosomes and reorganize the cytoskeleton and cell membrane to acquire the distinctive biconcave shape of red blood cells.

Each developmental stage is characterized by a distinct transcriptional program, with a burst of erythroid-specific genes\' expression occurring at the early stage of development, followed by the gradual silencing of the transcriptome in late erythroid precursors ([@bib1], [@bib28]). These transcriptional changes are governed by complex regulatory networks, consisting of the functional interplay between genomic regulatory regions (i.e., promoters and enhancers) and master transcription factors. In particular, enhancers are the primary determinants of the gene expression program at the early stage of erythropoiesis ([@bib19], [@bib41], [@bib54]).

GATA2 and GATA1 transcription factors are essential for hematopoietic development and recognize similar GATA DNA motifs. GATA2 has a fundamental role in the expansion and survival of hematopoietic stem and progenitor cells (HSPC) and has been mainly described as a positive regulator of gene expression ([@bib49]). GATA1 is the master regulator of erythropoiesis and functions as an activator or repressor depending on the chromatin context and cofactors ([@bib13]). During erythropoiesis, the *GATA2* locus is shut down, whereas GATA1 levels increase, and this transcriptional change (known as *GATA factor switching*) is essential for survival and terminal differentiation of erythroid cells ([@bib6], [@bib33], [@bib47]). As an example, in murine erythroid progenitors, GATA2 enhances the expression of the stem cell factor receptor KIT, which is essential for their proliferation, whereas GATA1 is responsible for KIT down-regulation, which is required to achieve terminal differentiation ([@bib17], [@bib24], [@bib34]). A GATA2-to-GATA1 exchange takes place at specific genomic sites containing GATA DNA motifs ("GATA switching sites") and is critical to determine changes in the expression of target genes during erythroid development ([@bib6], [@bib10], [@bib19], [@bib33]). Several studies investigated GATA2 and GATA1 genome-wide occupancy in both mouse ([@bib9], [@bib10], [@bib31], [@bib53], [@bib55]) and human hematopoietic cells ([@bib5], [@bib14], [@bib18], [@bib19], [@bib29], [@bib43], [@bib46], [@bib54]). However, a comprehensive analysis of the dynamics of GATA factor binding to regulatory elements during erythroid commitment and differentiation is still lacking.

Here, we investigated the epigenetic and transcriptional changes occurring during human erythroid development. Integrating RNA sequencing (RNA-seq) data, chromation immunopreciptation sequencing (ChIP-seq) analysis of histone modifications typical of regulatory elements, and GATA factors\' binding profiles in human HSPC, early erythroid progenitors, and late precursors, we shed light on the regulatory mechanisms controlling stage-specific transcriptional programs and on the distinct role of GATA1 in the early and late phases of human erythropoiesis. The novel key points of our study are as follows: (1) a progressive decrease of H3K27 acetylation, a histone mark typical of active regulatory regions, is a major epigenetic change during erythroid development and is associated with a reduction of active enhancers and super-enhancers (SEs) upon differentiation; (2) promoters are the primary determinants of the gene expression program at the late stage of erythropoiesis; (3) integration of the chromatin landscape and GATA1 occupancy revealed that GATA1 plays a crucial role in determining the global transcriptional changes occurring during erythroid development; (4) GATA1 exerts its transcriptional activity by occupying mainly promoters in late precursors; and (5) differently from mouse cells, GATA1 activates *KIT* gene expression in human erythroid progenitors.

Results {#sec2}
=======

Transcriptional Profiling Reveals Major Changes of Gene Expression upon Erythroid Differentiation {#sec2.1}
-------------------------------------------------------------------------------------------------

To gain a comprehensive view of gene expression changes occurring during erythroid development, we performed RNA-seq analysis of human HSPC differentiated *in vitro* into early committed erythroid progenitors (E-Prog; CD34^low^CD36^+^GYPA^low^) and late erythroid precursors (E-Prec; CD34^−^CD36^+^GYPA^high^) ([Figure 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). E-Prog contain BFU-E and CFU-E progenitors ([Figure S1](#mmc1){ref-type="supplementary-material"}C and [@bib41]), and E-Prec population consists mainly of polychromatic erythroid precursors ([Figure S1](#mmc1){ref-type="supplementary-material"}C and data not shown). Overall, most genes displayed a lower expression level in E-Prec compared with HSPC and E-Prog ([Figure S1](#mmc1){ref-type="supplementary-material"}D; [@bib1], [@bib51], [@bib44]). Supervised analysis identified 2,485 differentially expressed genes (DEGs) during commitment (1,203 up-regulated and 1,282 down-regulated in HSPC-to-E-Prog transition; [Figure S1](#mmc1){ref-type="supplementary-material"}E) and 6,496 DEGs upon differentiation (2,983 up-regulated and 3,513 down-regulated genes in E-Prog-to-E-Prec transition; [Figure S1](#mmc1){ref-type="supplementary-material"}E). We classified all 7,469 unique DEGs in eight groups, according to their modulation during erythroid development ([Figure 1](#fig1){ref-type="fig"}B). Some DEGs were up- or down-regulated only in one transition (groups 1 and 5 upon commitment and groups 3 and 7 upon differentiation); others were progressively modulated during erythroid development (groups 2 and 6) or showed a non-monotonic expression pattern (groups 4 and 8). Different gene expression patterns reflected specific biological processes ([Figure S1](#mmc1){ref-type="supplementary-material"}F). As reported in other studies ([@bib28], [@bib44], [@bib51]), genes progressively up-regulated during erythroid development (group 2) were related to hemoglobin synthesis and erythrocyte differentiation. Interestingly, we identified novel classes of genes specifically up-regulated during the differentiation phase (group 3), including genes involved in DNA packaging and chromosome condensation, in accordance with the heterochromatinization known to occur at late stages of erythropoiesis ([@bib21]). Conversely, HSPC-specific markers (i.e., CD34 and CD133) or genes involved in other blood lineages\' biology were down-regulated during commitment (group 5) or progressively down-regulated during erythroid development (group 6), whereas genes related to ribosome biogenesis were down-regulated in the differentiation phase (group 7), consistently with the ribosome loss occurring during terminal maturation ([@bib32]). Interestingly, genes up-regulated upon erythroid commitment and down-regulated during differentiation (group 4) were involved in metal ion transport, cell morphogenesis, cytokine production, and signaling pathways, and included *KIT*, a gene essential for E-Prog survival and proliferation that must be down-regulated to achieve terminal erythroid maturation ([@bib35]).Figure 1Changes in the Transcriptomic and Epigenomic Profile during Erythroid Development(A) Schematic representation of erythroid development. HSPC are committed toward the erythroid lineage giving rise to E-Prog that then differentiate in E-Prec. Gray bars describe the expression of CD34, CD36, and GYPA surface markers during erythroid development. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.(B) Different groups of DEGs, defined according to their modulation (up- or down-regulation) during erythroid commitment (HSPC to E-Prog) and differentiation (E-Prog to E-Prec). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.(C--E) Bar plots showing the number of promoters (C), enhancers (D), and super-enhancers (E) identified in each cell population. Promoters and enhancers were classified as active (H3K27ac^+^H3K27me3^-^), weak (H3K27ac^−^H3K27me3^-^), or bivalent (H3K27ac^−^H3K27me3^+^). Active enhancers were used as constituent enhancers to identify super-enhancers. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.(F--H) Heatmaps showing the dynamic usage of promoters (F), enhancers (G), and super-enhancers (H) during erythroid commitment and differentiation. Each row represents a regulatory region. The color code indicates active, weak, and bivalent regulatory regions at each stage of erythroid development. White color indicates absence of the regulatory region. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc2){ref-type="supplementary-material"}, [S3](#mmc3){ref-type="supplementary-material"}, and [S4](#mmc4){ref-type="supplementary-material"}.

Active Chromatin Regions Are Lost during Erythroid Commitment and Differentiation {#sec2.2}
---------------------------------------------------------------------------------

To investigate the chromatin changes occurring during erythroid development, we analyzed the genome-wide distribution of histone modifications typically associated with promoters (H3K4me3) and enhancers (H3K4me1), active regulatory regions (H3K27ac), and Polycomb repression (H3K27me3). The fraction of the genome enriched in H3K4me3 was comparable across all stages, whereas genome coverage for all other histone modifications was reduced in E-Prog and E-Prec compared with HSPC. In particular, the coverage of H3K27ac and the amount of H3 histones harboring this modification progressively decreased during erythroid development ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B).

To define the epigenetic landscape in a systematic manner, we exploited a machine learning approach to identify chromatin states using these four histone marks with a resolution of 200 bp. We defined five promoter states (H3K4me3^+^), four enhancer states (H3K4me1^+^), a polycomb-repressed state (H3K27me3^+^), and a quiescent state devoid of any histone mark ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Based on the presence of H3K27ac or H3K27me3, we classified promoter and enhancer states as active (H3K27ac^+^H3K27me3^-^), weak (H3K27ac^−^H3K27me3^-^), or bivalent (H3K27ac^−^H3K27me3^+^; [@bib12], [@bib40]). Finally, we merged contiguous genomic segments (see [Methods](#sec4){ref-type="sec"}) to define different sets (active, weak, and bivalent) of promoter and enhancer regions (with a minimum size of 400 bp) for each stage of erythroid development ([Tables S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc2){ref-type="supplementary-material"}, and [S3](#mmc3){ref-type="supplementary-material"}). Moreover, we defined SEs as clusters of active enhancers ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc4){ref-type="supplementary-material"}; [@bib50], [@bib16]). To validate our approach, we analyzed the expression levels of genes associated with different classes of regulatory elements. Genes associated with active regulatory regions showed higher expression levels compared with genes associated with weak or bivalent regions, which were expressed at medium and low levels, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). We identified around 20,000 promoters in HSPC and E-Prog and 15,868 in E-Prec ([Figure 1](#fig1){ref-type="fig"}C), more than 45,000 enhancers in HSPC and E-Prog and only 21,337 in E-Prec [Figure 1](#fig1){ref-type="fig"}D, and 497 SEs in HSPC, 436 in E-Prog, and only 135 in E-Prec ([Figure 1](#fig1){ref-type="fig"}E). Most of the regulatory elements were active in HSPC, whereas the fraction of active promoters ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D), enhancers ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D), and SEs ([Figure 1](#fig1){ref-type="fig"}E) diminished in E-Prog and E-Prec in accordance with the progressive loss of H3K27ac during erythroid development.

Interestingly, most promoters were shared during erythroid development, with only 10% being stage specific ([Figures 1](#fig1){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}A). Promoters that maintained an active state throughout erythroid development drove the expression of genes involved in common cell functions, as cell metabolism, cell cycle, and chromatin organization ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Bivalent promoters that maintained their state in both commitment and differentiation or completely lost H3K4me3 were associated with genes involved in non-hematopoietic tissue and organ development that need to be repressed to maintain lineage fidelity ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Interestingly, genes related to erythropoiesis were associated with either active promoters that maintained their state during the entire erythroid development or E-Prec-specific promoters.

Enhancer usage dramatically changed during commitment and differentiation, resulting in almost 40% enhancers being stage-specific in each cell type ([Figures 1](#fig1){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}C). Genes targeted by active and weak stage-specific enhancers in HSPC were mainly involved in leukocyte differentiation, whereas in E-Prog they were related to chromosome organization, cytoskeleton and plasma membrane organization, and cell cycle, and in E-Prec they were related to erythrocyte differentiation, chromatin organization, and autophagy ([Figure S3](#mmc1){ref-type="supplementary-material"}D).

SEs\' usage was almost completely stage specific, with less than 30% SEs identified in a single cell type shared with the other stages ([Figures 1](#fig1){ref-type="fig"}H and [S4](#mmc1){ref-type="supplementary-material"}A). HSPC-specific SEs were annotated to genes involved in leukocyte biology ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and to stem cell markers as *DNMT3A*, *CD34*, *PROM1* (*CD133*), *RUNX2/RUNX3*, *FLI1*, *ERG,* and *GFI1* ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Instead, genes targeted by E-Prog- and E-Prec-specific SEs were mostly related to erythrocyte biology, such as *CD55*, *RHAG*, *HBS1L*, *CD36*, *SLC44A1*, *SLC40A1,* and *SPTA1* in E-Prog and *RHD RBM38*, *HEMGN*, *TMEM56*, *SLC2A1*, *SLC22A23*, *SLC25A37*, *SLC22A4,* and *HBE1* (beta-globin locus control region) in E-Prec ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Only few loci (n = 60; e.g., *KIT* gene) displayed a combination of common and stage-specific SEs, suggesting a fine modulation of the expression of these genes during erythroid differentiation (see [Figure 4](#fig4){ref-type="fig"}).

GATA Transcription Factors\' Occupancy during Erythroid Commitment and Differentiation {#sec2.3}
--------------------------------------------------------------------------------------

To elucidate how GATA factors regulate gene expression during erythroid development, we analyzed GATA2 and GATA1 binding profiles in HSPC, E-Prog, and E-Prec. Although GATA2 mRNA levels were comparable in HSPC and E-Prog ([Figure 2](#fig2){ref-type="fig"}A), GATA2 protein was present at high levels in HSPC and decreased during erythroid development ([Figure 2](#fig2){ref-type="fig"}B). GATA1 protein was mainly present in E-Prog and substantially reduced in E-Prec ([Figures 2](#fig2){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A and [@bib29]) despite the progressive increase of *GATA1* mRNA expression during differentiation ([Figure 2](#fig2){ref-type="fig"}A). The dynamic expression of GATA proteins clearly emerged when analyzing GATA factors\' genome-wide occupancy. Indeed, the large number of GATA2-binding sites (BS) identified in HSPC (n = 15,171) drastically decreased in E-Prog cells (n = 419) and was reduced to zero in E-Prec ([Figure 2](#fig2){ref-type="fig"}C, [Table S5](#mmc1){ref-type="supplementary-material"} and [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). Similarly, we identified more than 23,000 GATA1 BS in E-Prog and almost half of these in E-Prec (n = 11,005), whereas no GATA1 BS was recovered in HSPC ([Figure 2](#fig2){ref-type="fig"}C, [Table S5](#mmc1){ref-type="supplementary-material"} and [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). Virtually all GATA2 BS were HSPC specific, and one-third of them underwent a GATA2-to-GATA1 switch during HSPC-to-E-Prog transition and 40% of these remained bound by GATA1 in E-Prec ([Figure 2](#fig2){ref-type="fig"}C). E-Prog and E-Prec shared ∼7,000 GATA1 BS, whereas ∼16,000 and ∼4,000 stage-specific GATA1 BS were identified in E-Prog and E-Prec, respectively ([Figure 2](#fig2){ref-type="fig"}C). These data indicate that GATA1 occupies and regulates common and different genes during the early and late stages of erythroid development.Figure 2GATA Factors Occupancy during Erythroid Development(A) Expression levels of GATA2 and GATA1 in HSPC, E-Prog, and E-Prec by RNA-seq. Data were plotted as mean with SEM.(B) Western blot analysis of GATA2 and GATA1 in the nuclear fraction of HSPC, E-Prog, and E-Prec. Total H3 was used for normalization. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.(C) Heatmap showing GATA2 and GATA1 BS dynamics during erythroid commitment and differentiation. Each row represents a GATA factor BS. The number of BS identified in each population is reported below the heatmap. Dashed lines separate common and stage-specific BS. See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc1){ref-type="supplementary-material"}.(D) GATA2 and GATA1 BS distribution within regulatory regions in HSPC, E-Prog, and E-Prec. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.(E) Heatmap showing different groups of GATA2-and GATA1-targeted genes in HSPC, E-Prog, and E-Prec. We defined GATA2- and GATA1-targeted genes as the three nearest genes (with a maximum distance of 100 kb) to each GATA-targeted regulatory region. Each target gene can be associated with one or more GATA BS.(F) Heatmap showing the enrichment of the different groups of GATA factor target genes, as defined in (E), in genes with different expression patterns (as defined in [Figure 1](#fig1){ref-type="fig"}B). Gray-scale indicates enrichment p value. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.(G) Gene ontology enrichment analysis of GATA2- and GATA1-targeted genes. Enriched Biological Process (BP) terms are shown on the y axis; different groups of GATA factor target genes, as defined in (E), are shown on the x axis. Dots are color coded based on the enrichment q-values; dot size indicates the fraction of genes in each BP term.

Genomic regions targeted by GATA2 were enriched in DNA motifs for ETS and RUNX factors, preferentially expressed in earlier stages of erythroid development, whereas GATA1-targeted regions contained motifs for the erythroid-specific KLF1 factor, and, in E-Prec, for the ubiquitous SP1 and NFY factors that occupy preferentially promoter elements ([Figure S5](#mmc1){ref-type="supplementary-material"}D).

Mapping GATA BS to regulatory regions revealed that the two factors targeted only a small fraction of promoters and enhancers, whereas GATA2 and GATA1 occupied the majority of SEs in HSPC and in E-Prog/E-Prec, respectively ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C and [Tables S2](#mmc2){ref-type="supplementary-material"}, [S3](#mmc3){ref-type="supplementary-material"}, and [S4](#mmc4){ref-type="supplementary-material"}). Among BS mapped to regulatory regions, 72% HSPC GATA2 BS were located within enhancers and SEs. GATA1 occupies both enhancers/SEs (58%) and promoters (42%) in E-Prog, whereas in E-Prec, GATA1 mainly targeted promoter regions (72%, [Figure 2](#fig2){ref-type="fig"}D). These results indicate that GATA1 may exert its transcriptional activity by occupying both enhancers and promoters in committed erythroid progenitors and mainly promoters in more differentiated precursors.

We then associated GATA-occupied regulatory regions with their target genes. Around half of GATA2-targeted genes in HSPC were targeted by GATA1 in E-Prog ([Figure 2](#fig2){ref-type="fig"}E) and more than 75% of them presented at least one GATA switching site. Interestingly, GATA1 occupied common and different sets of genes in E-Prog and E-Prec ([Figure 2](#fig2){ref-type="fig"}E). Genes targeted only by GATA2 in HSPC (group A) were down-regulated during erythroid development ([Figure 2](#fig2){ref-type="fig"}F) and are involved in immune system biological processes ([Figure 2](#fig2){ref-type="fig"}G). This analysis suggests that these genes are activated by GATA2 in HSPC, whereas loss of GATA2 binding during erythroid development leads to their down-regulation. Genes undergoing GATA2-to-GATA1 exchange upon erythroid commitment were either up-regulated or their expression remained stable, suggesting that GATA1 increases or sustains their expression in E-Prog, whereas GATA2 might repress them or maintain their low expression in HSPC. Then, these genes were either turned off during differentiation, when losing GATA1 binding in E-Prec (group B; [Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E), or up-regulated during erythroid development, if still targeted by GATA1 in E-Prec (group C; [Figures 2](#fig2){ref-type="fig"}F, [S6](#mmc1){ref-type="supplementary-material"}D, and S6E). Group B was functionally enriched in immune cell activation and hematopoiesis, whereas group C was enriched in erythropoiesis, histone modifications, cell cycle, and autophagy ([Figure 2](#fig2){ref-type="fig"}G). In E-Prog and E-Prec (group F), GATA1 occupied genes that were up-regulated during erythroid development ([Figures 2](#fig2){ref-type="fig"}F, [S6](#mmc1){ref-type="supplementary-material"}D, and S6E) and related to heme metabolic process, membrane lipid distribution, and chromatin organization ([Figure 2](#fig2){ref-type="fig"}G). Finally, genes specifically targeted by GATA1 in E-Prec (group G) were up-regulated upon differentiation and involved in cell cycle and autophagy ([Figures 2](#fig2){ref-type="fig"}F and 2G). These results suggest that GATA1 exerts mainly activating functions during human erythroid development.

Transcriptional Changes in Erythropoiesis Are Associated with a Complex Interplay between Regulatory Elements and GATA Factors\' Binding {#sec2.4}
----------------------------------------------------------------------------------------------------------------------------------------

To unveil how the interplay between regulatory elements and GATA factors influences transcriptional regulation during erythropoiesis, we assigned the different regulatory elements to each DEG and evaluated the enrichment in GATA factor BS at each stage of erythroid development ([Figure 3](#fig3){ref-type="fig"}). In particular, we generated a gene-centered matrix that contains the total coverage of all promoters and enhancers assigned to each DEG at each cell stage. This procedure allowed grouping of DEGs in 19 clusters based on their different chromatin landscapes. These clusters were either controlled by promoters only (clusters 1, 2, 8, 13, and 17) or by the combined action of promoters and enhancers ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, the chromatin landscape of DEGs was more heterogeneous than their transcriptional status, as genes associated with different chromatin landscapes showed the same expression pattern during erythroid development ([Figures 3](#fig3){ref-type="fig"}A and 3B). In particular, clusters from 1 to 7 comprised genes that were mostly up-regulated during erythroid commitment and differentiation (e.g., genes involved in erythrocyte biology and chromatin reorganization; [Figures 3](#fig3){ref-type="fig"}B and 3C) despite their different chromatin landscapes ([Figure 3](#fig3){ref-type="fig"}A). Promoters of these genes were already marked by H3K27ac in HSPC, before erythroid induction, and maintained an active state during the entire development ([Figure 3](#fig3){ref-type="fig"}A). These data indicate that promoters of up-regulated genes are bookmarked in earlier stages of erythroid development. Active enhancers, if present, either did not change their state during erythroid development or were even lost, particularly upon terminal differentiation ([Figure 3](#fig3){ref-type="fig"}A), indicating that enhancers play a minor role in the transcriptional up-regulation occurring during E-Prog-to-E-Prec transition. On the contrary, genes in clusters from 8 to 16 (e.g., genes related to leukocyte biology and non-hematopoietic development) showed a sharp change in their chromatin landscape, characterized by the loss of active regulatory elements during erythroid development accompanied by the concomitant decrease in the expression levels ([Figures 3](#fig3){ref-type="fig"}A--3C).Figure 3Chromatin Landscape Defines Clusters of DEGs(A) Heatmap representing the clustering of the gene-centered matrix containing the total coverage of the promoters and enhancers annotated to each DEG. DEGs are clustered according to the total extension of the associated regulatory regions. Each column represents a DEG, and each row, the extension (in kb) of the associated regulatory elements in each cell stage. Color scale indicates the total extension as log~10~(coverage \[kb\]).(B) Heatmap showing cluster enrichment in genes with different expression patterns (as defined in [Figure 1](#fig1){ref-type="fig"}B). Color scale indicates the statistical significance of the enrichment calculated by a Fisher\'s exact test.(C) Biological process terms (BPs) enriched in each group are shown on the y axis; DEG clusters, as defined in [Figure 3](#fig3){ref-type="fig"}A, are shown on the x axis. Dots are color coded based on the enrichment q-values; dot size indicates the fraction of genes in each Gene Ontology term. DEGs of clusters 1--7, mostly up-regulated during erythroid commitment and differentiation, are functionally annotated to erythropoiesis, chromatin organization, cell cycle, and autophagy BPs. Genes within clusters from 8 to 19, mostly down-regulated during erythroid development, were related to immune cell biology (12, 14--16) or to the development of unrelated tissues (17--19).(D and E) Heatmaps showing cluster enrichment in GATA factors BS within promoters (D) and in GATA factor BS within enhancers (E). Color scale indicates the statistical significance of the enrichment calculated by a Fisher\'s exact test.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

To investigate this partial dichotomy between epigenetic and transcriptional profiles, we evaluated the enrichment in GATA factors\' BS within promoters and enhancers associated with each cluster of DEGs. As expected, GATA2 targeted mostly enhancers in HSPC, whereas GATA1 binds both promoters and enhancers in E-Prog and mainly promoters in E-Prec ([Figures 3](#fig3){ref-type="fig"}D and 3E). Considering clusters of up-regulated genes (from 1 to 7), GATA2 BS were enriched at promoters or enhancers of few clusters in HSPC, whereas in E-Prog and E-Prec, GATA1 binding was enriched within active promoters of virtually all clusters and within active and weak enhancers of some of them ([Figures 3](#fig3){ref-type="fig"}D and 3E). These findings indicate that GATA1 plays a role in up-regulating these genes during erythroid development mainly through the binding of active promoters, especially in late precursors, whereas GATA2 likely maintains their low activity in HSPC. Clusters of down-regulated genes (from 8 to 16) were characterized by an enrichment of GATA2 BS at active and weak enhancers in HSPC and by an enrichment of GATA1 BS at weak promoters and active and weak enhancers in E-Prog and at weak and bivalent promoters and weak enhancers in E-Prec ([Figures 3](#fig3){ref-type="fig"}D and 3E). This suggests that, in HSPC, GATA2 binding at enhancers might play a role in boosting the expression of these genes, which is still sustained by GATA1 in E-Prog. Then, the loss of GATA1 binding at active enhancers or the binding of GATA1 to weak or bivalent promoters might induce the transcriptional silencing of these genes in E-Prec. In E-Prog, GATA1 BS were also enriched at bivalent promoters of lowly expressed genes involved in the development of unrelated tissues (clusters 17--19; [Figure 3](#fig3){ref-type="fig"}C) indicating that, when binding at bivalent promoters, GATA1 might act as a transcriptional repressor.

Overall, virtually all the clusters enriched in GATA2 BS within enhancers in HSPC showed enrichment in GATA1 BS in E-Prog and E-Prec, suggesting that the transition from GATA2- to GATA1-mediated gene regulation occurs mainly at enhancer regions ([Figure 3](#fig3){ref-type="fig"}E). Of note, 37% enhancers targeted by GATA2 in HSPC contain GATA switching sites.

GATA1-bound regions associated with induced genes were enriched in motifs for KLF1 and E2F4 factors ([Figure S7](#mmc1){ref-type="supplementary-material"}), which are up-regulated during erythroid development and play a fundamental role in erythroid differentiation and proliferation ([@bib25], [@bib45]). Conversely, GATA1-occupied regions associated with down-regulated genes contained motifs for ETS factors (e.g., ERG, FLI1, and PU.1; [Figure S7](#mmc1){ref-type="supplementary-material"}), mostly expressed in HSPC and down-regulated during erythroid development, and fundamental for the maintenance of HSC and the development of other hematopoietic lineages ([@bib4], [@bib8], [@bib26], [@bib36], [@bib39], [@bib52]). Thus the low expression of ETS factors in erythroid cells and the consequent lack of ETS factor binding to these genes could contribute to the silencing of genes involved in non-erythroid functions ([@bib52]). Finally, composite GATA:TAL1 motifs were enriched in GATA-occupied regulatory regions associated with both up- and down-regulated genes ([Figure S7](#mmc1){ref-type="supplementary-material"}), suggesting a role for TAL1 in both gene activation and gene repression ([@bib20], [@bib37], [@bib42], [@bib48]).

A Novel GATA1-Dependent Super-enhancer Sustains KIT Expression in Erythroid Progenitors {#sec2.5}
---------------------------------------------------------------------------------------

To prove that this interplay between regulatory elements and GATA factors\' binding is crucial to control gene expression during erythroid development, we focused on the *KIT* gene. A precise regulation of KIT expression is required for erythroid progenitor survival and proliferation and to achieve terminal erythroid maturation ([@bib35]). Indeed, we found that, in HSPC, *KIT* mRNA levels were relatively low and ∼65% cells poorly expressed KIT on the cell surface (median fluorescence intensity \[MFI\] = 17) ([Figures 4](#fig4){ref-type="fig"}A and 4B). Upon commitment, *KIT* transcription significantly increased (∼14 fold) and almost all E-Prog (∼93%) expressed KIT at high levels (MFI = 189) ([Figures 4](#fig4){ref-type="fig"}A and 4B). In E-Prec, *KIT* gene was substantially down-regulated with less than 55% cells still expressing low levels of KIT (MFI = 65) ([Figures 4](#fig4){ref-type="fig"}A and 4B).Figure 4Epigenetic Regulation and Chromatin Interactions in the Human KIT Locus during Erythroid Development(A) *KIT* mRNA expression levels in HSPC, E-Prog, and E-Prec, as determined by RT-qPCR. Data were plotted as mean with SEM. ∗p \< 0.05 (unpaired t test).(B) Flow cytometry analysis of KIT expression during erythroid commitment and differentiation. The percentage of KIT^+^ cells and the MFI (median fluorescence intensity) are shown. Data were plotted as mean with SEM. ∗∗p \< 0.01; ∗∗∗p \< 0.001; ∗∗∗∗p \< 0.0001 (unpaired t test).(C) Regulatory elements and GATA factors BS within the *KIT* locus. Green boxes indicate SEs. Orange dashed boxes indicate the constituent enhancers within the E-Prog-specific super-enhancer. Enhancer I and II (E-I and E-II) show the highest H3K27ac peaks. Enhancer III (E-III) is homologous to the mouse −114 enhancer. Enhancer IV (E-IV) undergoes GATA2-to-GATA1 switch. SNPs mapping to the E-Prog-specific super-enhancer are indicated.(D) Chromatin interactions within the *KIT* locus in undifferentiated (Day 0) and differentiated (Day 7) HUDEP-2 cells. We used as anchor a genomic fragment containing the *KIT* promoter (flanked by solid black lines). HindIII digestion fragments of interest are flanked by dashed black lines. Distances on the x axis are in kb counting from the transcription start site (TSS) of the *KIT* gene. *KIT* promoter interacts with Enhancer I and II only in KIT^high^ HUDEP-2 undifferentiated cells. See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

In mouse KIT^+^ progenitor cells, GATA2 activates *KIT* expression through the binding of an enhancer located −114 kb upstream of the gene ([@bib24]). Upon erythroid differentiation, this enhancer is occupied by GATA1, which induces *KIT* down-regulation ([@bib24]). The analysis of regulatory elements during human erythroid development revealed that both *KIT* promoter and *KIT*-associated enhancers were active in HSPC and E-Prog and lost H3K27ac upon differentiation ([Figure 4](#fig4){ref-type="fig"}C; cluster 9 in [Figure 3](#fig3){ref-type="fig"}A). Moreover, *KIT* regulatory elements were targeted by GATA2 in HSPC and by GATA1 upon erythroid commitment ([Figure 4](#fig4){ref-type="fig"}C; group B in [Figure 2](#fig2){ref-type="fig"}F and cluster 9 of [Figure 3](#fig3){ref-type="fig"}D). In particular, we identified three SEs that could contribute to *KIT* transcriptional regulation during erythropoiesis, i.e., an SE located within *KIT* first intron in both HSPC and E-Prog, an HSPC-specific SE located +160/+180 kb downstream of *KIT* TSS ([@bib2]), and an E-Prog-specific SE located −118/-70 kb upstream of *KIT* TSS ([Figure 4](#fig4){ref-type="fig"}C). This latter SE comprised two main constituent active enhancers (Enhancer I and II) marked by high H3K27ac levels and bound by GATA1. Interestingly, upon differentiation, both Enhancer I and II lost H3K27ac and Enhancer II lost GATA1 binding ([Figure 4](#fig4){ref-type="fig"}C). In addition, the E-Prog-specific SE contains two additional GATA1-occupied active enhancers that show lower H3K27ac levels compared with Enhancers I and II: (1) Enhancer III that is homologous to the murine −114-kb enhancer but is not targeted by GATA2 in KIT^+^ progenitors as in the mouse system and (2) Enhancer IV that is occupied by GATA2 in HSPC (as a weak enhancer) and is targeted by GATA1 upon erythroid commitment ([Figure 4](#fig4){ref-type="fig"}C). Of note, in HSPC, besides Enhancer IV, GATA2 occupies also a weak enhancer upstream of the E-Prog-specific SE, suggesting that it may contribute to sustain *KIT* expression in HSPC ([Figure 4](#fig4){ref-type="fig"}). Interestingly, two SNPs (rs2703485 and rs218264) associated with red blood cell phenotypes map to the GATA1 BS in Enhancer I and Enhancer IV, respectively ([Figure 4](#fig4){ref-type="fig"}C; [@bib3]).

To demonstrate that GATA1 binding to the highly acetylated Enhancer I and II is essential to sustain KIT expression in human erythroid progenitors, we performed chromatin conformation capture (3C) and Cas9-mediated genome editing in HUDEP-2 cells. HUDEP-2 is an immortalized erythroid progenitor cell line ([@bib27]) that, similarly to E-Prog, expresses high levels of KIT when undifferentiated (Day0) and that, as in the E-Prog-to-E-Prec transition, down-regulates KIT upon differentiation (Day 7) ([Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). Moreover, undifferentiated HUDEP-2 cells present accessible chromatin regions mapping to the E-Prog-specific *KIT* enhancers ([Figure S8](#mmc1){ref-type="supplementary-material"}C), suggesting that these regulatory elements are active in this cell line ([@bib30]). 3C experiments evidenced that, only in undifferentiated KIT^high^ HUDEP-2 cells, the *KIT* promoter interacts with Enhancer I and II ([Figure 4](#fig4){ref-type="fig"}D) and that Enhancer I and II interact with each other ([Figures S8](#mmc1){ref-type="supplementary-material"}D and S8E). This indicates the presence, in human erythroid progenitors, of an active chromatin hub containing the *KIT* promoter and its active regulatory elements. We then transfected KIT^high^ HUDEP-2 cells with plasmids expressing a Cas9-GFP fusion protein and guide RNAs deleting Enhancer I or II or specifically disrupting their respective GATA1 BS ([Figure 5](#fig5){ref-type="fig"}A). Both the deletion of *KIT* Enhancer I or II and the disruption of GATA1 BS strongly reduced *KIT* gene expression, the percentage of KIT-expressing cells, and KIT MFI in the GFP^+^-edited fraction ([Figures 5](#fig5){ref-type="fig"}B--5E and [S9](#mmc1){ref-type="supplementary-material"}), indicating that GATA1 binding at Enhancer I and II plays a crucial role in boosting *KIT* expression in erythroid progenitor cells. Notably, the lower expression of KIT was accompanied by a marked increase in the expression of the erythroid differentiation marker GYPA, with a trend in decreased GATA2 and increased GATA1 mRNA levels ([Figure 5](#fig5){ref-type="fig"}F).Figure 5CRISPR/Cas9-Mediated Disruption of E-Prog-Specific *KIT* Regulatory Elements(A) Schematic representation of the genomic regions and GATA1 BS in the *KIT* locus targeted using the CRISPR/Cas9 system. Red boxes indicate unedited wild-type Enhancer I or II, and white dots indicate unedited wild-type GATA1 BS within the enhancers (Ctr). Black boxes indicate Enhancer I or II deletion (Δ Enh. I and Δ Enh. II). Black dots indicate GATA1 BS disruption (Δ BS I and Δ BS II).(B) *KIT* expression levels in control and edited cells, as determined by RT-qPCR. Control samples (Ctr) were transfected with plasmids encoding for Cas9-GFP and a guide RNA targeting the luciferase gene. mRNA levels were expressed as fold change versus control cells. Data were plotted as mean with SEM.(C--E) Flow cytometry analysis of GFP and KIT expression in control and edited cells. For all the edited samples, both percentage of KIT^high^ cells (C and D) and KIT MFI (C and E) in the GFP^+^ populations were reduced compared with control cells. Percentage of KIT^high^ cells and KIT MFI were expressed as fold change versus control cells. Data were plotted as mean with SEM.(F) *GYPA*, *GATA2, and GATA1* expression levels by RT-qPCR in control and edited cells. mRNA levels were expressed as fold change versus control cells. Data were plotted as mean with SEM.(B and D--F) ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; ∗∗∗∗p \< 0.0001 (unpaired t test).

Discussion {#sec3}
==========

In this study, we analyzed the usage of regulatory elements and GATA factor dynamic occupancy in multipotent human primary HSPCs and in their erythroid progeny, including human early erythroid progenitors ([@bib41]) and late polychromatic erythroid precursors.

During erythropoiesis, inhibition of histone acetylation and increase in histone deacetylation play a critical role in chromatin condensation and enucleation of erythroid precursors ([@bib22], [@bib23], [@bib38]). Our analysis of the epigenetic landscapes of human HSPC, early erythroid progenitors, and late precursors revealed for the first time a progressive decrease of H3K27ac abundance and genome-wide coverage during erythroid development, accompanied by the up-regulation of genes involved in chromatin condensation and by the overall reduction in gene expression upon differentiation. These results suggest that the decrease of H3K27ac during erythropoiesis contributes to the heterochromatin formation and the consequent global gene silencing at late stage of erythroid development. This extensive epigenetic change influences the regulatory mechanisms controlling transcription, in particular in late erythroid precursors. Indeed, we found a reduced number of active H3K27ac^+^ regulatory elements, in particular enhancers and SEs, upon differentiation, suggesting that enhancer decommissioning occurs at the late stage of erythropoiesis. In accordance, gene expression in late precursors is mainly sustained by promoters and weak H3K27ac^−^ enhancers, and the few SEs identified in E-Prec control the transcription of only a subset of stage-specific highly expressed genes. Our findings are consistent with the decreased number of chromatin accessibility peaks in polychromatic human erythroid precursors ([@bib29], [@bib43]).

The coordinate action of GATA factors has a fundamental role in the transcriptional regulation of erythropoiesis. The "GATA factor switching" ([@bib6], [@bib33], [@bib47]) occurred in E-Prog, where GATA2 protein levels decreased, whereas the amount of GATA1 protein increased, resulting in a prevalent and specific chromatin occupancy of GATA2 in HSPC and GATA1 in E-Prog. Several genes regulated by GATA2 in HSPC were targeted by GATA1 in E-Prog, and the transition from GATA2 to GATA1-mediated gene regulation can occur via a GATA2-to-GATA1 exchange at the same BS (GATA switching sites) and/or through the alternative binding of GATA2 and GATA1 to different sites within the regulatory regions associated with the target gene. Interestingly, for differentially expressed genes, GATA switch occurs mostly at enhancer regions, and either leads to gene up-regulation or does not significantly change gene expression in E-Prog.

However, most GATA1 functions during erythropoiesis occur via *de novo* binding at open chromatin regions. Interestingly, GATA1 targeted common and distinct sets of genes in E-Prog and E-Prec, displaying different binding preferences. Indeed, in E-Prog, GATA1 occupied both promoters and enhancers (or SEs), whereas in E-Prec GATA1 mainly bound promoters. This change in GATA1 binding preferences during E-Prog-to-E-Prec transition together with the diminished enhancer usage observed in E-Prec highlights a novel pivotal role of promoter regions as determinants of the transcriptional program activated during terminal erythroid differentiation. This novel finding is a unique feature of erythroid precursors, as previous studies indicate that enhancers play a main role in defining cell fate at the early stage of development ([@bib19], [@bib41], [@bib54]).

To better investigate the interplay between regulatory elements and GATA factors in determining gene transcription during erythropoiesis, we used an integrative bioinformatics approach. Our results showed that investigating the chromatin landscape dynamic alone is not sufficient to infer the transcriptional modulations that occur during erythroid development, and that integrating the binding profiles of key master regulators, as GATA2 and GATA1, is essential to understand the epigenetic mechanisms governing the transcriptional changes. Moreover, our findings evidenced that GATA1 binding in different chromatin contexts consistently correlates with its dual activity as transcriptional activator or repressor. In fact, GATA1 binding at active regulatory regions (mainly promoters) is associated with a positive transcriptional regulation of the target gene (as for genes related to erythrocyte differentiation and homeostasis). Conversely, GATA1 binding at weak (in E-Prec) or bivalent (in both E-Prog and E-Prec) promoters correlates with the transcriptional silencing of the target genes (as for genes related to leukocyte differentiation or development of unrelated tissues).

Importantly, we performed validation studies of regulatory elements identified in the *KIT* locus. In mouse erythroid cells, several regulatory elements were identified upstream of the *KIT* gene or within its introns, and GATA2 is known to activate *KIT* expression in early progenitors, whereas GATA1 is responsible for *KIT* down-regulation upon differentiation ([@bib7], [@bib17], [@bib24], [@bib34]). However, little is known about the transcriptional regulation of *KIT* gene in human cells ([@bib2], [@bib41]). Here, we identified an E-Prog-specific SE upstream of *KIT* gene targeted by GATA1. Our results demonstrate that GATA1 binding at the E-Prog-specific SE is required for high-level *KIT* expression in human erythroid progenitors. Interestingly, the enhancer homologous to the murine −114-kb regulatory region (which was associated with high KIT expression when occupied by GATA2 in mouse progenitors and to KIT down-regulation when occupied by GATA1 in mouse erythroid precursors; [@bib24]) is not targeted by GATA2 but only by GATA1 in KIT^+^ E-Prog. Altogether, these data indicate that, differently from mouse erythroid cells, GATA1 activates *KIT* expression in human erythroid progenitors, supporting its up-regulation during erythroid commitment.

Several genes are known to be differentially regulated in human versus murine erythropoiesis ([@bib1]). Notably, some genes upregulated during human erythropoiesis and down-regulated during murine erythropoiesis (e.g., RAPGEF2, MAP2K3, and RNF187; [@bib1]) were indeed associated with active regulatory regions targeted by GATA1 in E-Prog and E-Prec ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E).

Overall, our stage-specific analysis of the transcriptional and epigenetic profiles and GATA factors\' occupancy at key stages of human erythropoiesis provides new insights into the complex transcriptional regulatory mechanisms that control human erythroid commitment and differentiation, dissecting the pivotal role of GATA1 at both early and late stages of erythropoiesis.

Limitations of the Study {#sec3.1}
------------------------

Given the high number of cells required to detect GATA factor binding by ChIP-seq, we analyzed mixed populations of erythroid progenitors (E-Prog: BFU-E, and CFU-E) and precursors (E-Prec: mainly polychromatic precursors). Therefore, our analyses may have a lower definition compared with transcriptomic and epigenomic studies analyzing highly purified erythroid progenitors and precursors ([@bib1], [@bib28], [@bib29], [@bib43]).

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The accession number for all RNA-seq and ChIP-seq data reported in this paper is GEO:[GSE124165](ncbi-geo:GSE124165){#intref0010}.
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